Health Condition 1: C00-D49- Neoplasms Health Condition 2: null- Patients who have developed medicine related osteonecrosis of jaw (MRONJ) lesions due to antiresorptive drugs like Bisphophonates
Conditions
Interventions
Intervention1: Platelet Rich fibrin: Platelet rich fibrin is derived from patients own blood by centrifuging 10 ml whole blood in controlled laboratory environment.
The PRF formed in each individual
Sponsors
Tata Memorial Centre
Eligibility
Inclusion criteria
Inclusion criteria: 1) Patients who are on, or who have had, treatment with antiresorptives or antiangiogenic agents i.e. Zoledronate, Alodronate, Pamidronate, Ibandronate, Denosumab, Sunitinib, Sorafenib, Bevacizumab and who have necrosis of jaw bone (ONJ) 2) Patients with ONJ sites that had failed to heal for 8 weeks or longer despite continuous treatment with antimicrobial drugs 3) Age > 18 years
Exclusion criteria
Exclusion criteria: 1. Patients who have been given radiotherapy to head neck region 2. Patients who have neoplastic involvement of the jaw. 3. Patients in whom MRONJ extends till lower border of mandible / sinus floor / zygoma requiring major ostectomies for debridement of necrosed bone
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete resolution of MRONJ lesionTimepoint: 1 month 4 Months | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Down grading of MRONJ lesion 2. Symptoms of MRONJ pain, swelling, dischargeTimepoint: 1 month 4 months | — |
Countries
India
Contacts
Public ContactDr Sandeep Gurav
Tata Memorial Hospital
Outcome results
None listed